Thyroid cancer is the least deadly cancer, with a 98.3% five-year relative survival rate based on data from the National Cancer Institute’s SEER program (2016–2022). Prostate cancer follows closely at 98.2%, then melanoma at 94.7%, testicular cancer at 94.6%, and breast cancer at 91.9%. These numbers represent averages across all stages at diagnosis, and survival for early-stage versions of these cancers is even higher.
Why Thyroid Cancer Tops the List
The most common form of thyroid cancer, called papillary thyroid cancer, has a five-year survival rate above 99% when caught while still in the thyroid gland. Even when it spreads to nearby lymph nodes, survival remains at 99%. This is partly because papillary thyroid cancer tends to grow slowly and responds well to treatment, and partly because many thyroid cancers are found incidentally during imaging scans done for other reasons, catching them early.
That said, not all thyroid cancers are equal. Rarer subtypes like anaplastic thyroid cancer are far more aggressive and carry a much worse prognosis. When people refer to thyroid cancer as “the least deadly cancer,” they’re typically talking about the papillary type, which accounts for the vast majority of cases.
Other Cancers With High Survival Rates
Prostate cancer’s 98.2% survival rate reflects the fact that most cases are diagnosed while still localized and tend to grow slowly. Many men with low-risk prostate cancer are monitored rather than treated immediately, a strategy called active surveillance. For locally advanced or more aggressive prostate cancer, long-term outcomes depend heavily on treatment. One large Scandinavian trial found that adding radiation to hormone therapy cut the 15-year death rate from prostate cancer roughly in half, from 34% to 17%.
Melanoma, the most serious type of skin cancer, still has a 94.7% overall survival rate because the majority of cases are caught early, when the cancer is still thin and confined to the skin. Testicular cancer sits at 94.6% and is notable for responding extremely well to treatment even when diagnosed at more advanced stages. Breast cancer rounds out the top five at 91.9%, with survival above 90% in countries like the United States and Australia, though rates vary dramatically worldwide. In India, for example, five-year breast cancer survival is around 66%.
Basal Cell Carcinoma: A Special Case
If you’ve seen claims that basal cell carcinoma is the “least deadly” cancer, there’s some truth to that, but it’s hard to quantify. Basal cell carcinoma is the single most common cancer in humans, yet it grows so slowly and so rarely spreads that it isn’t even tracked by cancer registries the way other cancers are. Deaths from it are exceptionally rare. It’s typically excluded from survival comparisons because it occupies a different category altogether.
What “Survival Rate” Actually Means
A five-year relative survival rate compares the likelihood that someone diagnosed with a particular cancer will be alive five years later to the likelihood for someone in the general population of the same age and sex. A rate of 98.3% for thyroid cancer means that, on average, people diagnosed with thyroid cancer are nearly as likely to be alive in five years as people who were never diagnosed. It does not mean that 1.7% of patients die from the disease. Some of that gap reflects deaths from unrelated causes or rarer, more aggressive subtypes pulling the average down.
These rates also reflect a snapshot in time. The SEER figures cited here are based on people diagnosed between 2016 and 2022, so they capture treatment options available during that window. For cancers where treatment has been improving rapidly, current survival may be somewhat better than what the statistics show.
High Survival Doesn’t Mean Zero Consequences
Cancers with excellent survival rates can still significantly affect quality of life, especially through treatment side effects. Thyroid cancer surgery can cause voice changes and chronically low calcium levels, requiring lifelong medication. Prostate cancer treatment carries risks of incontinence and sexual dysfunction. Breast cancer surgery and radiation can lead to complications like lymphedema, a chronic swelling condition.
For the slowest-growing versions of these cancers, there’s a real concern about overtreatment. Some thyroid and prostate cancers grow so slowly that they would never cause symptoms during a person’s lifetime, yet once diagnosed, the pressure to treat can be strong. Active surveillance programs now exist for low-risk thyroid, prostate, and certain breast cancers, allowing people to avoid surgery and its side effects while being closely monitored for any signs of progression. The goal is to treat only when the cancer truly poses a threat, sparing people unnecessary harm from a diagnosis that, statistically, may never affect their health.